Gut Bacteria Linked to Cancer Types and Treatment Side Effects

A significant study analyzing stool samples from over 1,300 cancer patients has revealed distinct gut microbiome patterns linked to different cancers and treatment responses. Researchers identified unique microbial signatures associated with five major cancer groups, including neuroendocrine tumors, liver and bile duct cancers, esophageal cancer, lymphoid leukemia, and multiple myeloma.

The research highlighted notable differences in patients diagnosed at younger ages, particularly for early-onset colorectal and breast cancers, which have seen recent increases. Younger patients with colorectal cancer showed higher levels of lactate and the bacterium Veillonella parvula, while younger breast cancer patients exhibited changes in bacterial species and lower levels of primary bile acids.

Furthermore, the study suggests the microbiome may help predict treatment side effects. Patients receiving the chemotherapy drug 5-fluorouracil who later experienced diarrhea had lower levels of specific bacterial genes before treatment. This finding raises the possibility of future microbiome-based tests to identify patients at higher risk for adverse effects, though further validation is needed.

The research also found gut bacteria associated with survival outcomes in several cancer types, including colorectal, liver, ovarian, and prostate cancers, as well as melanoma. These findings underscore the growing importance of the gut microbiome in cancer care, potentially leading to new strategies for improving survival and reducing treatment toxicities.